Oncology Central

Will nanobiosensors change therapeutic drug monitoring? The case of methotrexate

0

Nanobiosensors have emerged as potentially revolutionary technologies to perform therapeutic drug monitoring (TDM). Pharmacokinetics of therapeutic drugs may vary importantly such that TDM can provide valuable information to enable safer treatments and for establishing a personalized course of treatments.

To view restricted content, please:
Share:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.